Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AMN107: tightening the grip of imatinib.

Cancer cell - 1 Feb 2005

O'Hare Thomas, Walters Denise K, Deininger Michael W N, Druker Brian J

Abstract excerpt

The Abl inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses are relatively uncommon in newly diagnosed patients, but are the rule in patients with more advanced disease. Mutations in the BCR-ABL gene are the most common cause of relapse. Working from the imatinib chemical structure, a higher-affinity family member, AMN107, was designed. AMN107 is approximately...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Models, Chemical

Share to Piperazines

Share to Pyrimidines

Share to Recurrence

Source

Identifiers

PMID: 15710324
DOI: 10.1016/j.ccr.2005.01.020

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AMN107: tightening the grip of imatinib.PMID 15710324Read ↗

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.Semantic proximity Read ↗

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.Semantic proximity Read ↗

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.Semantic proximity Read ↗

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.Semantic proximity Read ↗

Overriding imatinib resistance with a novel ABL kinase inhibitor.Semantic proximity Read ↗

Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.Semantic proximity Read ↗

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblSemantic proximity Read ↗

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.Semantic proximity Read ↗

The second generation of BCR-ABL tyrosine kinase inhibitors.Semantic proximity Read ↗

The BCR-ABL Story: Bench to Bedside and BackSemantic proximity Read ↗

HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistanceSemantic proximity Read ↗

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.